Loading
PSMA PET-CT was 27 percentage points more accurate than CT and bone scan for finding spread in men with high-risk prostate cancer before treatment, with less radiation and more influence on management, and it has replaced conventional imaging where available.
Randomised multicentre trial of 302 men with high-risk localised prostate cancer randomised to conventional imaging (CT and bone scan) or gallium-68 PSMA PET-CT for staging, with crossover imaging to define a reference standard.
Accuracy was 92 percent for PSMA PET-CT against 65 percent for conventional imaging, with higher sensitivity (85 versus 38 percent) and specificity, fewer equivocal results, lower radiation dose and more frequent management change.
PSMA PET-CT is the preferred staging investigation for high-risk prostate cancer and for biochemical recurrence, though most treatment trials were designed with conventional imaging.
Shares PSMA expression by PET (PSMA-positive), Theranostics, Prostate cancer (KEGG map), PSMA.
Shares PSMA expression by PET (PSMA-positive), Theranostics, Prostate cancer (KEGG map), PSMA.
Shares PSMA expression by PET (PSMA-positive), Theranostics, PSMA, PSMA PET.
Shares PSMA expression by PET (PSMA-positive), Theranostics, PSMA, PSMA PET.
Shares PSMA expression by PET (PSMA-positive), Theranostics, PSMA, PSMA PET.
Shares proPSMA, PSMA, PSMA PET, Prostate cancer.
Shares proPSMA, PSMA, PSMA PET, Prostate cancer.
Shares PSMA, Localised prostate cancer, high and very high risk, PSMA PET, Prostate cancer roadmap: from Huggins and the discovery that a cancer can depend on a hormone, through the PSA epidemic and what it cost, the androgen receptor drugs, the DNA repair subset and PSMA, to a 2032 registry watch.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/